Abstract Number: 1990 • 2016 ACR/ARHP Annual Meeting
Increased Risk of Cardiovascular Events in Patients with Rheumatoid Arthritis over a 15 Year Time Period That Is Comparable to Type 2 Diabetes
Background/Purpose: recent cohort studies with long term follow up studying this risk are scarce.We report the results of a 15 year observational cohort study comparing…Abstract Number: 1991 • 2016 ACR/ARHP Annual Meeting
Risk of Incident Diabetes Mellitus and Its Association with Disease-Modifying Antirheumatic Drugs and Statins in Rheumatoid Arthritis
Background/Purpose: Diabetes mellitus (DM) is an important cardiovascular risk factor in RA. Although a few prior studies reported DM risk reduction with hydroxychloroquine (HCQ) and…Abstract Number: 1992 • 2016 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Is an Independent Risk Factor for Increased Insulin Resistance and Impaired Beta-Cell Function: Impact of Disease Activity
Background/Purpose: Increased insulin resistance and impaired β-cell function have been demonstrated in pts with rheumatoid arthritis (RA). The aim of our study was to investigate…Abstract Number: 1993 • 2016 ACR/ARHP Annual Meeting
The Risk of Stroke in Patients with Rheumatoid Arthritis and the Association with Competing Adverse Events
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk for infections, hospitalizations and cardiovascular (CV) events. The association of serious adverse events (SAE) with…Abstract Number: 1994 • 2016 ACR/ARHP Annual Meeting
Associations of Chronic Lung Comorbidity with Medications, Disease Activity, and All-Cause Mortality in Rheumatoid Arthritis
Background/Purpose: While the impact of interstitial lung disease (ILD) on mortality in RA has been demonstrated, less is known about the influence of other lung…Abstract Number: 1995 • 2016 ACR/ARHP Annual Meeting
Smoking Is Associated with Unfavorable Flare/ Remission Pattern in Patients with Rheumatoid Arthritis
Background/Purpose: Smoking is well recognized as a risk factor for rheumatoid arthritis (RA), and determinant of RA disease activity, severity, response to therapy, and possibly…Abstract Number: 1997 • 2016 ACR/ARHP Annual Meeting
Non-Medical Switch from Originator to Biosimilar Infliximab in Patients with Inflammatory Arthritis – Impact on s-Infliximab and Antidrug-Antibodies. Results from the Danish Rheumatologic Biobank and the Danbio Registry
Background/Purpose: According to national guidelines issued in 2015, a non-medical switch from originator infliximab (IFX) (Remicade) to biosimilar Remsima was conducted in all Danish patients…Abstract Number: 1998 • 2016 ACR/ARHP Annual Meeting
Long-Term Registry Data in 4498 Patients with Rheumatoid Arthritis Indicate a Similar Safety but a Different Drug Retention Between Abatacept, Rituximab and Tocilizumab
Three non-TNF targeted biologics – rituximab, abatacept, and tocilizumab – are widely used, notably in TNF-IR patients. We aimed to compare the efficacy and safety…Abstract Number: 1999 • 2016 ACR/ARHP Annual Meeting
Claims-Based Analysis of Cost-Effectiveness Among Patients with Rheumatoid Arthritis Who Switched from a Tumor Necrosis Factor Inhibitor to Another Targeted Disease-Modifying Antirheumatic Drug
Background/Purpose: Patients with rheumatoid arthritis (RA) who have an inadequate response to a tumor necrosis factor inhibitor (TNFi) can switch to another targeted disease-modifying antirheumatic…Abstract Number: 2000 • 2016 ACR/ARHP Annual Meeting
Incidence of Cancer in Patients with Rheumatoid Arthritis and a History of Cancer Treated with Rituximab or Abatacept
Background/Purpose: Patients with a history of cancer were excluded from pivotal clinical trials evaluating biologics. Therefore, only registries can inform us on the incidence of…Abstract Number: 2001 • 2016 ACR/ARHP Annual Meeting
Perioperative Use of Synthetic Disease-Modifying Anti-Rheumatic Drugs or Tumor Necrosis Factor α Inhibitors Does Not Associate with Increased Rates of Post-Operative Infections
Background/Purpose: The aim of the study is to assess whether the risk of post-operative infectious complications in rheumatoid arthritis (RA) patients undergoing surgical procedures is…Abstract Number: 2002 • 2016 ACR/ARHP Annual Meeting
Differences in Features of Chronic Back Pain in First Degree Relatives of Patients with Ankylosing Spondylitis (AS) Compared to the U.S. Population
Background/Purpose: To compare the clinical features of spondyloarthritis in first degree relatives (FDRs) of patients with ankylosing spondylitis (AS) with chronic back pain (CBP) with…Abstract Number: 2003 • 2016 ACR/ARHP Annual Meeting
Validation of the ASAS Health Index: Results of a Multicenter International Study in 23 Countries
Background/Purpose: The ASAS Health Index (ASAS HI) was developed to measure functioning and health in patients with spondyloarthritis (SpA) aiming to better define the impact…Abstract Number: 2004 • 2016 ACR/ARHP Annual Meeting
Is Disease Activity Associated with Work Productivity Loss, Presenteeism and Absenteeism in Patients with Early Axial Spondyloarthritis? Results from the Spondyloarthritis Caught Early (SPACE)-Cohort
Background/Purpose: Disease activity has an important impact on work productivity in patients with Ankylosing Spondylitis (AS). However, if and to what extent this is the…Abstract Number: 2005 • 2016 ACR/ARHP Annual Meeting
Exploring the Window of Opportunity for Drug-Free Clinical Remission in Patients with Active, Very Early Peripheral Spondyloarthritis
Background/Purpose: To evaluate drug-free sustained clinical remission and clinical relapse after induction therapy with golimumab in patients with active peripheral Spondyloarthritis (pSpA) in a very…
ACR Meeting Abstracts